Our previous study suggested that the activation of the TGF‐β‐miR‐34a‐CCL22 axis could promote HCC cells disseminated into the portal venous system through the creation of an immune‐subversive microenvironment [7]. The gene discussed is CCL22; the disease is hepatocellular carcinoma.